Holen Sie sich die Stockscreener-App
744.66
0.18%
-1.95
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Sq - AD HOC NEWS
Quadrature Capital Ltd Has $34.31 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mackenzie Financial Corp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital Research Global Investors Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - The Globe and Mail
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Positive Obesity Phase 3 Trial Results - Yahoo Finance
Regeneron Science Talent Search: Jericho High senior Ashka Shah recounts experience at finals in D.C. - Newsday
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN) - Seeking Alpha
WINTON GROUP Ltd Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Franklin Resources Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Richard Bernstein Advisors LLC Sells 2,449 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Legal & General Group Plc Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital World Investors Acquires 32,348 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lowered by Capital International Inc. CA - MarketBeat
Capital International Investors Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Capital Group Private Client Services Inc. - MarketBeat
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment - The Manila Times
Regeneron Science Talent Search 2026 Recognizes America’s - GlobeNewswire
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative? - simplywall.st
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment - GlobeNewswire Inc.
Jefferies raises Regeneron stock price target on obesity drug data - Investing.com
Price Over Earnings Overview: Regeneron Pharmaceuticals - Benzinga
REGN: Dupixent and EYLEA HD fuel growth as pivotal pipeline readouts approach in 2024–2025 - TradingView
Capital International Ltd. CA Sells 5,999 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital International Sarl Has $26.31 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Swiss National Bank Has $172.06 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Russell Investments Group Ltd. Has $128.61 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Korea Investment CORP Purchases 5,181 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cowen Maintains Buy on Regeneron Pharmaceuticals, Inc. (REGN) March 2026 - Meyka
Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial - TechTarget
Regeneron (REGN) Reports Positive Phase 3 Results for Obesity Dr - GuruFocus
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Regeneron stock maintained at Buy by Truist on obesity drug data - Investing.com Canada
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China - BioSpace
Sienna Gestion Sells 9,627 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron-licensed obesity drug shows positive phase 3 results in China (REGN:NASDAQ) - Seeking Alpha
Vinva Investment Management Ltd Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Advances in Obesity Treatment with Promising Tr - GuruFocus
Olatorepatide obesity treatment licensed by Regeneron demonstrates positive phase 3 results in Chinese patients - marketscreener.com
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients - The Manila Times
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in ... - bdtonline.com
Jefferies Financial Group Inc. Acquires Shares of 25,535 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Natixis Advisors LLC Acquires 7,084 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by First Trust Advisors LP - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Victory Capital Management Inc. - MarketBeat
Pinnacle Associates Ltd. Has $47.34 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prevail Innovative Wealth Advisors LLC Acquires Shares of 7,628 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Rhenman & Partners Asset Management AB - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Dimensional Fund Advisors LP Sells 20,341 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Barclays PLC Sells 157,105 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Illumina Regeneron Alliance Targets Multiomics And Raises Valuation Questions - Yahoo Finance UK
Assessing Regeneron Pharmaceuticals (REGN) Valuation As Shares Trade Below Estimated Fair Value - simplywall.st
Is Regeneron (REGN) Still Attractively Priced After Mixed Recent Share Performance - Yahoo Finance
This Regeneron Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Barclays Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views - Benzinga
Here Are Friday’s Top Wall Street Analyst Research Calls: BorgWarner, CoreWeave, Intuit, Marvell Technology, Netflix, Okta, Regeneron Pharmaceuticals, Trade Desk, and More - 24/7 Wall St.
Picton Mahoney Asset Management Acquires 8,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure at $764.49 - Markets Mojo
P/E Ratio Insights for Regeneron Pharmaceuticals - Sahm
Barclays initiates Regeneron stock with Overweight on Dupixent growth - Investing.com
Focus Partners Advisor Solutions LLC Acquires Shares of 2,909 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dupixent Approvals Expand Regeneron’s Immunology Reach And Valuation Debate - Yahoo Finance
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):